Pair page
GHRP-2 with Tesamorelin
Mechanism-tag overlap and published literature for GHRP-2 and Tesamorelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrelin-receptor-agonistgrowth-hormone-secretagogue
fda-approved-ghrh-analogvisceral-adiposity
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying GHRP-2 and Tesamorelin have published these mechanism-level observations. Not a co-administration recommendation.
FDA-approved GHRH analog (Egrifta), originally for HIV-associated lipodystrophy. Used in physician-supervised contexts as the GHRH partner for GHRP-2.
Quick facts
GHRP-2
Tesamorelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2001 | GHRP-2 | Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174. PMID: 1… PMID 11238504 | human study |
| 2005 | GHRP-2 | Granado M, Priego T, Martín AI, Villanúa MA, López-Calderón A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288(3):E486-E492. PMID: 15507534. PMID 15507534 | preclinical, in vivo |
| 2004 | GHRP-2 | Doi N, Furukawa M, Sato C, Sasaki M, et al. Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):857-867. PMID: 15646370. (Foundational pharmacology characterization by Kaken.) PMID 15646370 | mechanism / discovery |
| 1999 | GHRP-2 | Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470. (Ghrelin discovery — endogenous ligand.) PMID 10604470 | mechanism / discovery |
| 1996 | GHRP-2 | Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID: 8688086. (GHS-R1a cloning.) PMID 8688086 | mechanism / discovery |
| 2017 | GHRP-2 | Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Medicc Rev. 2017. PMC5392015. (Class review of cytoprotective evidence.) | review |
| 2026 | GHRP-2 | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (GHRP family banned under S2.) | regulatory / registry |
| 2025 | GHRP-2 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025-2026. | regulatory / registry |
| — | GHRP-2 | Thomas A, Höppner S, Geyer H, et al. Determination of growth hormone-releasing peptides in serum by LC-MS/MS for sports drug testing. (WADA detection methodology applicable to GHRP-2.) | regulatory / registry |
| 2004 | GHRP-2 | Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-880. PMID: 15646371. (Safety pharmacology evaluation.) PMID 15646371 | research article |
| 2004 | GHRP-2 | Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP 102, WAY GPA 748. Drugs R D. 2004;5(4):236-239. PMID: 15230633. (Drug development profile.) PMID 15230633 | research article |
| 2001 | GHRP-2 | Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-1469. PMID: 11297568. PMID 11297568 | research article |
| 2010 | Tesamorelin | Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind place… PMID 20101189 | human trial, Phase 3 |
| — | Tesamorelin | ClinicalTrials.gov. NCT00123253, NCT00435136 (Phase 3 registration); NCT01263717 (JAMA liver fat); NCT02196831 (Lancet HIV NAFLD); NCT00675506 (Arch Neurol cognition). | human trial, Phase 3 |
| 2019 | Tesamorelin | Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038. PMID 31611038 | human trial |
| 2014 | Tesamorelin | Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357. PMID 25038357 | human trial |
| 2005 | Tesamorelin | Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287. PMID: 16052083. PMID 16052083 | human trial |
| 2004 | Tesamorelin | Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized, controlled trial. JAMA. 2004;292(2):210-218. PMID: 15249570. PMID 15249570 | human trial |
| 2012 | Tesamorelin | Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.… PMID 22869065 | human study |
| 2011 | Tesamorelin | Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. Clin Infect Dis. 2011;53(11):1150-1158. PMID: 22016502. PMID 22016502 | human study |
| 2008 | Tesamorelin | Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. PMID: 18690162. PMID 18690162 | human study |
| 2007 | Tesamorelin | Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338. PMID 18057338 | human study |
| 2011 | Tesamorelin | Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PMID: 21668043. PMID 21668043 | review |
| 2026 | Tesamorelin | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have GHRP-2 and Tesamorelin been studied together?
Researchers have published mechanistic-level co-administration discussion of GHRP-2 and Tesamorelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do GHRP-2 and Tesamorelin share?
GHRP-2 and Tesamorelin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of GHRP-2 and Tesamorelin?
GHRP-2: Investigational (Category 2 bulk). Tesamorelin: Approved (2010). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on GHRP-2 and Tesamorelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the GHRP-2 profile and the Tesamorelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026